A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)

Background: Bevacizumab (Avastin®, Roche), which is used in cancer therapy, is the ‘parent’ molecule from which ranibizumab (Lucentis®, Novartis) was derived for the treatment of neovascular age-related macular degeneration (nAMD). There were reports in the literature on the effectiveness of bevaciz...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Usha Chakravarthy, Simon P Harding, Chris A Rogers, Susan Downes, Andrew J Lotery, Helen A Dakin, Lucy Culliford, Lauren J Scott, Rachel L Nash, Jodi Taylor, Alyson Muldrew, Jayashree Sahni, Sarah Wordsworth, James Raftery, Tunde Peto, Barnaby C Reeves, for the IVAN Investigators
Formato: Artigo
Idioma:Inglês
Publicado em: NIHR Journals Library 2015-10-01
Colecção:Health Technology Assessment
Assuntos:
randomised controlled trial
effectiveness
cost-effectiveness
treatment
inhibition
vascular endothelial growth factor
age
neovascularisation
ivan
bevacizumab
ranibizumab
macular degeneration
Acesso em linha:https://doi.org/10.3310/hta19780
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados